Long-term complete response to anti-programmed-death-1 monotherapy in a patient with relapsed and refractory ovarian adenocarcinoma: A case report

Figure 1 Serum carbohydrate antigen 125 over the patient’s treatment course. After three courses of anti-programmed cell death-1 treatment, the patient’s carbohydrate antigen 125 decreased from 2000 U/mL to 27.7 U/mL, which was within the normal range. C125: Carbohydrate antigen 125; CD: Carboplatin and doxorubicin hydrochloride liposome; TC: Paclitaxel and carboplatin.

Figure 2 Contrast of the patient’s chest computed tomography. A and B: Chest computed tomography (CT) in April 2020 before administration of anti-programmed cell death-1 (PD-1) therapy. The orange arrows indicate metastases; C and D: Chest CT in January 2021, 9 months after initiation of anti-PD-1 therapy. The metastases have disappeared.